Top Abstract Purchase Related
Home
>
Node
>
Subnode

Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors

Arkin, S.; Blei, F.; Fetten, J.; Foulke, R.; Gilchrist, G.S.; Heisel, M.A.; Key, N.; Kisker, C.T.; Kitchen, C.; Shafer, F.E.; Shah, P.C.; Strickland, D.

Blood Coagulation and Fibrinolysis An International Journal in Haemostasis and Thrombosis 11(3): 255-259

2000

ISSN/ISBN: 0957-5235
PMID: 10870806
Document Number: 525992
This open-label, emergency-use study evaluated the efficacy and safety of activated human coagulation factor VIIa (recombinant) (rFVIIa) (NovoSeven; Novo Nordisk Pharmaceuticals, Inc., New Jersey, USA) in treating limb-threatening joint or muscle bleeds in 17 patients with haemophilia A or B and six patients with acquired inhibitors to factor VIII or factor IX. All patients had previously failed on one or more alternative therapies. rFVIIa administration was effective or partially effective in controlling joint or muscle bleeds in 34 out of 35 (97%) bleeding episodes; in 23 patients, 14 of 17 (82%) muscle bleeds and 16 of 18 (89%) joint bleeds were effectively controlled. These findings suggest that rFVIIa is an effective and well-tolerated therapeutic option in the management of joint or muscle haemorrhage in patients with haemophilia and in patients with acquired inhibitors.

Document emailed within 1 workday
Secure & encrypted payments

Pruthi, R.K.; Mathew, P.; Valentino, L.A.; Sumner, M.J.; Seremetis, S.; Hoots, W.K. 2007: Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial Thrombosis and Haemostasis 98(4): 726-732
Guillet, B.; Pinganaud, C.; Proulle, V.; Dreyfus, M.; Lambert, T. 2002: Myocardial infarction occurring in a case of acquired haemophilia during the treatment course with recombinant activated factor VIi Thrombosis and Haemostasis 88(4): 698-699
Grinţescu, I.; Tulbure, D.; Mirea, L. 2006: Activated recombinant factor VIi (Novoseven) in multiple trauma patients: an outcome analysis Chirurgia 101(6): 615-624
Hay, C.R.; Lozier, J.N.; Lee, C.A.; Laffan, M.; Tradati, F.; Santagostino, E.; Ciavarella, N.; Schiavoni, M.; Fukui, H.; Yoshioka, A.; Teitel, J.; Mannucci, P.M.; Kasper, C.K. 1996: Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: the results of an international survey Thrombosis and Haemostasis 75(1): 25-29
Johannessen, M.; Andreasen, R.B.; Nordfang, O. 2000: Decline of factor VIIi and factor IX inhibitors during long-term treatment with NovoSeven Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 11(3): 239-242
Girolami, A.; Burul, A.; Cappellato, G.; Dal Bo Zanon, R. 1979: Electroimmunoassay of factor IX in patients with liver damage and vitamin K unresponsive coagulation disorder Folia Haematologica 106(1): 65-71
Vyhovs'ka, I.I.; Karol', I.S.; Fedak, L.M.; Tsytsyk, O.I. 2004: Use of recombinant activated factor VIi (NovoSeven) in the treatment of a patient with idiopathic thrombocytopenic purpura complicated with subarachnoid and parenchimatous hemorrhage Likars'ka Sprava 7: 77-81
Kim, D.J.; Girolami, A.; James, H.L. 1996: Characterization of recombinant human coagulation factor XFriuli Thrombosis and Haemostasis 75(2): 313-317
Gram, J.; Jespersen, J.; Pedersen, J.K. 1985: Diagnostic and clinical aspects in patients with acquired circulating coagulation inhibitors Ugeskrift for Laeger 147(16): 1319-1322
Bialas, T.; Kolitz, J.; Levi, E.; Polivka, A.; Oez, S.; Miller, G.; Welte, K. 1988: Distinction of partially purified human natural killer cytotoxic factor from recombinant human tumor necrosis factor and recombinant human lymphotoxin Cancer Research 48(4): 891-898
Abbruzzese, J.L.; Levin, B.; Ajani, J.A.; Faintuch, J.S.; Saks, S.; Patt, Y.Z.; Edwards, C.; Ende, K.; Gutterman, J.U. 1989: Phase i trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer Cancer Research 49(14): 4057-4061
Jorquera, J.I.; Carmona, E.; Aznar, J.A.; Peiró, A.; Sánchez-Cuenca, J.M. 1985: A standardized method for measuring anti-F VIII: C inhibitors in haemophilia a by coagulation inhibition in agarose gel Thrombosis and Haemostasis 54(2): 377-380
Roosendaal, G.; Lafeber, F.P.J.G. 2007: Prophylactic treatment with clotting factor to prevent joint damage in patients with severe haemophilia: costs versus benefits Nederlands Tijdschrift Voor Geneeskunde 151(47): 2606-2608
Zwaveling, J.H.; Maring, J.K.; Mulder, A.B.; Bom, V.J.; van Ginkel, R.J.; Schraffordt Koops, H.; Girbes, A.R.; Hoekstra, H.J.; van der Meer, J. 1996: Effects of hyperthermic isolated limb perfusion with recombinant tumor necrosis factor alpha and melphalan on the human fibrinolytic system Cancer Research 56(17): 3948-3953
Green, D. 1994: Immunosuppression of patients with acquired factor VIIi inhibitors Seminars in Hematology 31(2 Suppl 4: 60-61
Fukutake, K. 2000: Current status of hemophilia patients and recombinant coagulation factor concentrates in Japan Seminars in Thrombosis and Hemostasis 26(1): 29-32
Škunca, Željka.; Peraica, A.Planinc. 2016: Treatment of Severe Acquired Haemophilia A with Immunosuppressive Agent: A Case Report of One Patient Collegium Antropologicum 40(2): 139-143
Kessler, C.M.; Ludlam, C.A. 1993: The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group Seminars in Hematology 30(2 Suppl. 1): 22-27
Galstian, G.M.; Kolosova, I.V. 2014: Using recombinant activated blood coagulation factor VIi for treatment of hemorrhagic syndrome in patients with thrombocytopenia Anesteziologiia i Reanimatologiia 59(6): 60-66
van Gorkom, J.; Kibuga, D.K. 1996: Cost-effectiveness and total costs of three alternative strategies for the prevention and management of severe skin reactions attributable to thiacetazone in the treatment of Human Immunodeficiency Virus positive patients with tuberculosis in Kenya Tubercle and Lung Disease: the Official Journal of the International Union Against Tuberculosis and Lung Disease 77(1): 30-36